The community suggests that GLP-1 (glucagon-like peptide-1 receptor agonist) medications possess beneficial properties for longevity and systemic health that extend beyond simple weight loss, notably through a direct action on cardiovascular, cerebral, and inflammatory tissues.

noli's read

Current research, notably the cited SELECT study, confirms major cardiovascular benefits in overweight patients, with a significant reduction in the risk of myocardial infarction and stroke (Randomized clinical trial, NEJM). The idea that these effects are independent of weight loss is an actively studied hypothesis: meta-analyses suggest a reduction in systemic inflammation and an improvement in endothelial function, which supports the idea of a broader biological mechanism. However, asserting that these effects apply universally to metabolically healthy individuals remains an unproven extrapolation, as the majority of data comes from cohorts suffering from metabolic pathologies. The 'dementia prevention' aspect is still at the stage of early observational studies and requires confirmation through dedicated clinical trials. It is scientifically premature to consider these molecules as universal longevity agents for healthy subjects without cardiovascular risk. The community shows convergent enthusiasm, viewing these molecules as a major breakthrough, despite a cautious minority highlighting the absence of data on lean or healthy subjects.

the sources

1. 1Wilding JPH et al. (STEP 1) 2021
2. 2Jastreboff AM et al. (SURMOUNT-1) 2022
3. 3Jastreboff AM et al. 2023
4. 4Wilding JPH et al. (STEP 1 extension) 2022
5. 5r/longevity